Home  >  MEDTECH  > Roche acquires IQuum to strengthen offerings in molecular d...
Apr 7th, 2014
Roche acquires IQuum to strengthen offerings in molecular diagnostics
Send to a friend

IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics

Roche announced today the acquisition of IQuum, Inc. (IQuum) based in Marlborough, Massachusetts, USA. IQuum is a privately held company focused on developing point of care offerings for the molecular diagnostics market. Under the terms of the agreement, Roche will pay IQuum shareholders USD 275 million upfront and up to USD 175 million in contingent product related milestones. The transaction is subject to customary closing conditions.

The acquisition will provide Roche with access to IQuum’s Laboratory-in-a-tube (Liat™) System, which enables healthcare workers to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training. The Liat™ Analyzer and Liat™ Influenza A/B Assay, the first test available for use on the system, produce reliable and accurate lab-like results and are CE marked and FDA cleared.

“With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment. Patients will benefit from on-the-spot and accurate diagnoses, which will allow healthcare professionals to make rapid, informed treatment decisions in flexible settings,” said Roland Diggelmann, COO of Roche Diagnostics. “We welcome IQuum’s employees, who will continue to focus on the development and manufacturing of the Liat™ Analyzer and assays.

“We are very excited to continue developing innovative molecular diagnostics solutions as part of the Roche Molecular Diagnostics team,” said Shuqi Chen, Ph.D., CEO and founder of IQuum. “Roche is the ideal company to deliver on the promise of our point of care molecular diagnostics technology. We are fully committed to the continued success of IQuum’s employees, products and pipeline.”

Once the transaction is complete, IQuum will be integrated into Roche Molecular Diagnostics.

Yole Développement comments, by Benjamin Roussel, Activity Leader - MedTech:

Microfluidics is an enabling technology enabling miniaturization and integration of laboratory protocols into portable devices. A number of technologies have been introduced so far and despite a slow start, the outlook for the industry in the next 10 years is very positive. Major diagnostics companies (Alere, Abbott Point of Care, BD Diagnostics, Cepheid, Abaxis…) have launched successful point of care products based on microfluidic technology in the past few years. Through the acquisition of IQuum, Roche is now obviously entering the point of care diagnostics race.

Yole Développement will publish in May 2014, an update of the report “Point Of Care Testing: Applications of Microfluidic Technologies”. This new report will provide an in-depth analysis of the point of care market, detail market forecasts, an overview of nearly 60 new technologies (commercialized or close to the market) with information on the commercial status, targeted application, technology description, sample volume, sensitivity level, target price) in combination with Supply and Value chain analysis.
For more information about this upcoming report, please contact David Jourdan (jourdan@yole.fr)


About IQuum
IQuum is the leader in developing the lab-in-a-tube technology, a novel biological sample testing platform which provides revolutionary benefits to a broad cross section of the bioassay market. The Company's proprietary technology enables non-specialized personnel to perform more sophisticated biological sample testing in any setting with greater speed. Founded in 1998 by Dr. Shuqi Chen and his co-founder Keith Greenfield, the Company is commercializing its lab-in-a-tube technology and products for the clinical diagnostics, bio-defense, and industrial testing markets. For more information, please visit www.IQuum.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.


More MEDTECH news

Sep 16th
Sep 16th
Sep 12th
Sep 9th
Sep 8th
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr